70 Effects of relugolix combination therapy on endometriosis-associated pain and analgesic use in spirit studies: overall study and european populations

Venturella, Roberta; As‐Sanie, Sawsan; Kotarski, J; Mehedințu, Claudia; Imm, So Jung; Qurratul, A.; Becker, Christian M.

doi:10.1016/j.ejogrb.2021.11.131

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pooled analyses of SPIRIT 1 and 2, the treatment effect of relugolix combination therapy in the European [ 12 ] and the North American [ 13 ] subpopulations was consistent with that in the overall SPIRIT populations. In both subpopulations, relugolix combination therapy significantly reduced dysmenorrhoea and non-menstrual pelvic pain [ 12 , 13 ].…”

Section: Therapeutic Efficacy Of Relugolix/estradiol/norethisterone A...mentioning

confidence: 64%

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Blair

2024

Drugs

View full text Add to dashboard Cite

An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree ® (USA); Ryeqo ® (EU)] (hereafter referred to as relugolix combination therapy) has been approved in the USA for the management of moderate to severe pain associated with endometriosis in premenopausal women and in the EU for the symptomatic treatment of endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis. The gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix decreases estradiol and progesterone levels, while the addition of estradiol/norethisterone acetate mitigates hypoestrogenic effects including bone mineral density (BMD) loss and vasomotor symptoms. In two pivotal phase III trials, relugolix combination therapy significantly improved dysmenorrhoea and non-menstrual pelvic pain in premenopausal women with moderate to severe endometriosis. The combination also reduced overall pelvic pain and dyspareunia, reduced analgesic and opioid use, and improved health-related quality of life. The efficacy of relugolix combination therapy was sustained over the longer term (up to 2 years). Relugolix combination therapy was generally well tolerated and BMD loss over time was minimal. With the convenience of a once daily oral dosing regimen, relugolix combination therapy is a valuable addition to the options currently available for the management of endometriosis-associated pain. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-024-02018-3.

show abstract

Section: Therapeutic Efficacy Of Relugolix/estradiol/norethisterone A...mentioning

confidence: 64%

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Blair

2024

Drugs

View full text Add to dashboard Cite

show abstract

70 Effects of relugolix combination therapy on endometriosis-associated pain and analgesic use in spirit studies: overall study and european populations

Cited by 1 publication

References 0 publications

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Contact Info

Product

Resources

About